Lupus Science and Medicine Podcast

Challenging but achievable: reaching Low Lupus Disease Activity State (LLDAS) in childhood-onset SLE

Duane Peters from the Lupus Foundation of America talks to Dr Sylvia Kamphuis and Dr Javad Wahadat from the Erasmus Medical Center in Rotterdam in the Netherlands about aiming for a Low Lupus Disease Activity State (LLDAS) in children with systemic lupus erythematosus (SLE). They outline the difference between LLDAS and clinical remission (CR), and discuss how LLDAS may be a more achievable target for patients than CR that nevertheless still brings significant clinical benefits in terms of decreasing damage accrual and improving health-related quality of life.
Access the paper here: https://lupus.bmj.com/content/8/1/e000571

Could a high fiber diet positively impact the gut microbiome of SLE patients?

Duane Peters from the Lupus Foundation of America interviews Professor Iryna Kulyk from Indiana University in the USA and Professor Martin Kriegel from the University of Münster in Germany and Yale University in the USA. They discuss their study, presented at the Lupus 21st Century conference in September 2021, on the influence of the consumption of resistant starch (a type of dietary fiber) on the composition of the gut microbiota of lupus patients.
Access the abstract here: https://lupus.bmj.com/content/8/Suppl_2/A63.2.abstract

A new biomarker for cognitive dysfunction in SLE?

Duane Peters from the Lupus Foundation of America interviews Dr Erik Anderson and Dr Meggan Mackay from the Feinstein Institutes for Medical Research in New York in the USA. They discuss their study into imbalances in quinolinic acid and kynurenic acid levels in the brain in SLE patients, and propose that the ratio between these two metabolites could be used as a new biomarker or therapeutic target for cognitive dysfunction.
Access the paper here: https://lupus.bmj.com/content/8/1/e000559

Screening for cognitive dysfunction in SLE patients

Duane Peters from the Lupus Foundation of America interviews Jennifer He from the University of Western Ontario in Canada about her research into using neuropsychological battery tests to determine the degree of cognitive dysfunction in lupus patients. A high degree of variability in performance across multiple tests (a high dispersion score) is associated with a higher risk of cognitive dysfunction, so this can be a useful screening/diagnostic tool.
Access the paper here: https://lupus.bmj.com/content/8/1/e000511

Highlights of ACR Convergence 2021

Duane Peters from the Lupus Foundation of America interviews Dr Jill Buyon, one of LSM's Editors-in-Chief, about the highlights of ACR Convergence 2021, which was held virtually on 3-9 November (https://www.rheumatology.org/Annual-Meeting).

Personalised metabolite monitoring during pre-conception and pregnancy in SLE patients

Duane Peters from the Lupus Foundation of America interviews Francisca Lambert-Fliszar and Dr Evelyne Vinet from McGill University Health Centre in Canada. They discuss monitoring 6-mercaptopurine (6-MP) metabolite levels to enable personalisation of immunosuppressive therapies prior to conception or during pregnancy, in order to most effectively and safely control the disease during this critical time.
Access the paper here: https://lupus.bmj.com/content/8/1/e000519

Can you predict lupus nephritis outcomes using machine learning models?

Duane Peters from the Lupus Foundation of America interviews Dr Jim Oates from the Medical University of South Carolina and Ralph H. Johnson VA Medical Center in Charleston, USA. They discuss his paper on developing risk prediction models in lupus nephritis to predict outcomes at the point of diagnosis, which can be used as a decision support tool to help inform treatment strategies for patients.
Access the paper here: https://lupus.bmj.com/content/8/1/e000489

Highlights of the LUPUS & CORA 2021 joint congress

Duane Peters from the Lupus Foundation of America interviews Dr Ronald von Vollenhoven, one of LSM's Editors-in-Chief, about the highlights of the 14th International Congress on Systemic Lupus Erythematosus (LUPUS 2021) and the 6th International Congress on Controversies in Rheumatology and Autoimmunity (CORA). These events were held jointly as a virtual congress on 6-9 October 2021 (https://lupus2021.kenes.com) and showcased the best clinical, biological, and translational advances in the field of SLE and autoimmunity.

Identifying therapeutic targets in lupus nephritis: is obtaining research tissue via biopsy safe?

Duane Peters from the Lupus Foundation of America interviews Dr Jill Buyon, one of LSM's Editors-in-Chief, and Dr Philip Carlucci from New York University in the USA, a previous recipient of the LFA's Gina M. Finzi Memorial Student Summer Fellowship. They discuss their recent paper on the safety of kidney biopsies in patients with SLE enrolled in the Accelerating Medicines Partnership in the USA, which aims to identify potential targeted treatments for lupus nephritis.
Access the paper here: https://lupus.bmj.com/content/8/1/e000522

LSM’s first Journal Impact Factor™

Duane Peters from the Lupus Foundation of America interviews the Lupus Science & Medicine Editors-in-Chief, Professor Jill Buyon and Professor Ronald van Vollenhoven. They discuss the recent release of LSM's first Journal Impact Factor™, explaining how it has been calculated, and what it means for the journal, its authors and readers.
Access all the LSM journal metrics: https://lupus.bmj.com/pages/top-cited-articles/ and https://lupus.bmj.com/pages/about/.